https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Myovant_Sciences_Ltd.Myovant Sciences Ltd. - Revizia istoricului2026-04-06T05:39:41ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Myovant_Sciences_Ltd.&diff=431643&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Myovant Sciences Ltd. listata cu simbolul US.MYOV ==Descriere companie== Myovant Sciences Ltd. (http://myovant.com/) is a United Kingdom-based biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines and transformative advocacy. The Company’s two products include ORGOVYX, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with...2024-09-18T18:14:46Z<p>Pagină nouă: Pagina dedicata companiei Myovant Sciences Ltd. listata cu simbolul US.MYOV ==Descriere companie== Myovant Sciences Ltd. (http://myovant.com/) is a United Kingdom-based biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines and transformative advocacy. The Company’s two products include ORGOVYX, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Myovant Sciences Ltd. listata cu simbolul US.MYOV<br />
<br />
==Descriere companie==<br />
Myovant Sciences Ltd. (http://myovant.com/) is a United Kingdom-based biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines and transformative advocacy. The Company’s two products include ORGOVYX, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. It through its subsidiary, Myovant Sciences GmbH developing supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. It is developing Relugolix for the treatment of men with advanced prostate cancer. It is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.MYOV" /><br />
<br />
==Ultimele stiri despre Myovant Sciences Ltd. (US.MYOV)==<br />
<dynamicpagelist><br />
category=US.MYOV<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.MYOV]][[Categorie:Stiri despre companii]]</div>Admin